News

  • To pandemic preparedness and beyond: Accelerating novel antibody therapeutics through cross-border collaboration

    Innovation UBC [October 14, 2025] Through this new collaboration, Alloy will share its expertise and drug discovery technologies to support UBC’s efforts to develop antibody therapies for infectious disease targets. Working directly with UBC’s Pathogen Response Optimization by GENeratIng ThErapeutics Rationally (PROGENITER) program led by Dr. Sriram Subramaniam, Professor and Gobind Khorana Canada Excellence Research…

  • Delivering AI’s promise of better health care

    The University of British Columbia Faculty of Medicine News [June 12, 2025] Jump-started by a $22.5 million gift, UBC’s new AI and Health Network is deploying powerful artificial intelligence tools to drive health system innovation and improve patient care. One project, led by UBC professor Dr. Sriram Subramaniam, is combining AI with advanced cryo-electron microscopy…

  • $140M for UBC-led research hub to accelerate drug development and biomanufacturing

    The University of British Columbia Faculty of Medicine News [June 4, 2024] The funding supports four multidisciplinary research projects through Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH), a UBC-led alliance of more than 50 academic, industry, not-for-profit and health system partners that have come together to make Canada a leader in advanced immune-based therapeutics like RNA vaccines, antibody…

  • Federal government invests in pandemic rapid response lab at UBC

    Business in Vancouver [May 31, 2024] The federal government today announced $140 million in funding for Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH) out of the University of BC. It will support four multi-disciplinary research projects.

  • B.C. drug developers get boost with government funding for new manufacturing facility

    The Globe and Mail [May 31, 2024] UBC professor Sriram Subramaniam, meanwhile, will lead a project in partnership with local drug developers and pharmaceutical giant GSK, using cryo-electron microscopy and AI-enabled drug discovery to build a bank of antibody treatments for pathogens with pandemic-causing potential. “The total focus is on product that can be manufactured…

  • Canada’s Immuno-Engineering and Biomanufacturing Hub research teams awarded $140M in federal funding

    The University of British Columbia Faculty of Medicine News [May 6, 2024] The Government of Canada announced an investment of $140 million in projects associated with Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH) — a UBC-led national research hub with more than 50 academic, industry, not-for-profit and health sector partners.

  • UBC and the B.C. biotech boom

    The University of British Columbia Faculty of Medicine News [March 14, 2024] In a detailed exploration of British Columbia’s burgeoning biotech sector, The Globe and Mail recently cast a spotlight on Vancouver’s emergence as a global pharmaceutical leader and the pivotal role UBC researchers and UBC spin-off companies are playing in driving the sector’s growth.

  • B.C. biotech boom: Vancouver looks to join the global big leagues of modern medicine

    The Globe and Mail [March 9, 2024] Dr. Subramaniam was itching to be both an entrepreneur and academic as he searched for his next posting six years ago. He considered several offers but says “not one had the vision that UBC had” to support his dual ambitions. His $42-million research chair package included funding to…

  • Drug discovery at an atomic scale

    The University of British Columbia Faculty of Medicine News [February 26, 2024] UBC’s Dr. Sriram Subramaniam is using powerful cryo-electron microscopes to accelerate drug development for cancer, infectious diseases and more.

  • 2023 Faculty of Medicine Award Recipients

    The University of British Columbia Faculty of Medicine News [October 3, 2023] These awards celebrate extraordinary faculty and staff who exemplify our values — respect, integrity, compassion, collaboration and equity — and have made outstanding contributions toward our vision to transform health for everyone.